Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Hargrave, Darren; Bouffet, Éric; Tabori, Uri; Broniscer, Alberto; J. Cohen, Kenneth; R. Hansford, Jordan; Geoerger, Birgit; Hingorani, Pooja; J. Dunkel, Ira; W. Russo, Mark; Tseng, Lillian; Dasgupta, Kohinoor; Gasal, Eduard; A. Whitlock, James; W. Kieran, Mark

doi:10.1158/1078-0432.ccr-19-2177

Public

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Published in Clinical Cancer Research • Dec 6, 2019

Authors:

Darren Hargrave

Éric Bouffet

Uri Tabori

Abstract

Abstract Purpose: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with BRAF V600 mutation–positive pLGG may benefit from treatment with dabrafenib. Part 2 of a phase I/IIa study, open-label study (NCT01677741) explores the activity and safety of dabrafenib tre...

Subject

Refractory (planetary science)

Medicine

Glioma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!